Investigation Report on China’s Esomeprazole Market, 2009-2018

March 28, 2014

DUBLIN, March 28, 2014 /PRNewswire/ –

Dublin – Research and Markets (
http://www.researchandmarkets.com/research/lj5htc/investigation) has announced the
addition of the “Investigation Report on China’s Esomeprazole Market, 2009-2018″
[http://www.researchandmarkets.com/research/lj5htc/investigation ] report to their

http://photos.prnewswire.com/prnh/20130307/600769 )

Digestive system disease is one of the most frequently occurring diseases. According
to statistics from WHO, there are at least 250 million people worldwide suffering from
digestive system diseases, especially canker.

Inhibition of gastric acid secretion is the key treatment method for peptic ulcer,
duodenal ulcer and gastroesophageal reflux disease. The H+ / K+ ATPase in gastric parietal
cells can reduce gastric acid secretion. By inhibiting the functioning of this
transporter, the drug prevents formation of gastric acid.

The international drug market is always enthusiastic about anti-ulcer drug
development. It is very easy for products launched in the market to become bestsellers.
Esomeprazole is an outstanding example. Total sales revenue of Nexium (trade name of
esomeprazole produced by Astra Zeneca) is over tens of billions dollars, making it one of
the most important products from Astra Zeneca. Esomeprazole is a proton pump inhibitor
that appeared on the market in 2000. It is popular in the market because of high
bioavailability, effective and lasting inhibition of gastric acid and low toxic and side
effect. Once Ranbaxy Laboratories Limited submitted the application for simplified generic
esomeprazole capsules to FDA, Astra Zeneca sued the company for patent infringement.

However, Ranbaxy Laboratories Limited received temporary approval from FDA on February
5, 2008. Patent No. 94190335.4 is the most crucial patent for Nexium which expires in May
2014. To avoid time-consuming and costly patent infringement lawsuits, Astra Zeneca
announced in October 2011 that generic drug manufacturers with cooperation intention
needed to pay royalty before producing esomeprazole generic drugs. Over a dozen companies
including Dr. Reddy’s Laboratories signed the agreement with Astra Zeneca. Though generic
drugs take part of Nexium’s market, Astra Zeneca can recoup the loss by charging royalty.

Statistics shows that there are over 120 million people suffering from enterogastric
diseases in China, which is the most in the world. Incidence of peptic ulcer is 10% while
that of chronic gastritis is 30%.

Nexium produced by Astra Zeneca entered China in 2004. According to CRI’s
investigation on Chinese sample hospital market, the CAGR of the sales revenue of
esomeprazole was 50% from 2005 to 2012. It was spectacularly successful. At the end of
2013, Chinese market was completely dominated by products of Astra Zeneca.

Due to Nexium’s huge profit, pharmaceutical manufacturers including certain foreign
enterprises attempt to earn some profit by dodging patent infringement. For instance,
Hanmi Pharmaceutical Co., Ltd. submitted registration application of esomeprazole
strontium enteric-coated capsules to CFDA in 2008 and was rejected.

Key Topics Covered:

1 Relevant Concepts of Esomeprazole

2 Market Overview of Esomeprazole in China, 2009-2013

3 Investigation on Sales Value of Esomeprazole in China, 2009-2013

4 Investigation on Market Share of Major Esomeprazole Manufacturers in China,

5 Investigation on Market Size of Esomeprazole by Dosage Form in China, 2009-2013

6 Reference Price of Esomeprazole Produced by Different Enterprises in China Hospital
Market, 2014

7 Major Manufacturing Enterprises in China Esomeprazole Market, 2009-2014

8 Prospect of China Esomeprazole Market, 2014-2018

Companies Mentioned:

        - Boehringer Ingelheim
        - Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
        - Zhejiang Xianju Pharmaceutical Co., Ltd.

For more information visit


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net



SOURCE Research and Markets

Source: PR Newswire

comments powered by Disqus